<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="816">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150535</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21_10_18</org_study_id>
    <nct_id>NCT05150535</nct_id>
  </id_info>
  <brief_title>One Week Adjuvant Radiotherapy for Breast Cancer</brief_title>
  <official_title>A Prospective Study of One Week Accelerated Hypo-fractionation Adjuvant Radiotherapy in High-risk Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Cancer is the second leading cause of death after cerebrovascular strokes and is a&#xD;
           significant obstacle to each nation's future growth.&#xD;
&#xD;
        -  Worldwide, Breast cancer is the most common cancer in women and the 5th leading cause of&#xD;
           cancer related deaths that comes after lung cancer, colorectal cancer, liver cancer and&#xD;
           gastric cancer.&#xD;
&#xD;
        -  More than half of all breast cancer cases in the world occur in developing countries.&#xD;
           Egypt has a high mortality rate from breast cancer, with a rate of 21.3 per 100,000&#xD;
           cases. Breast cancer is diagnosed at an advanced stage in 60 to 70% of cases in Egypt.&#xD;
           The median age at diagnosis in Egypt is 48.5 years, which seems to be a decade younger&#xD;
           than in Europe and North America.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of acute grade 2 toxicity or higher from the treatment till 3 months (NCI_CTCAE).&#xD;
Each patient will be assesed weekly during radiotherapy and monthly for 3 months post radiotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chronic toxicity</measure>
    <time_frame>6 months post treatment up to 2 years</time_frame>
    <description>Rate of chronic toxicity grade 2 or higher ( NCI_CTCAE) from 6 months after radiotherapy up to 2 years.&#xD;
Each patient will be assessed before treatment and at 6,12 and 24 months from treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Rate of ipsilateral locoregional tumor recurrence proved by imaging and biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>From the starting point of treatment till the end of treatment ( 3 weeks in control arm and 1 week in experimental arm</time_frame>
    <description>Compliance to treatment (number of interrupted days of radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From time of diagnosis up to 2 years post radiotherapy</time_frame>
    <description>Overall survival (Number of the surviving patients for 2 years in each arm of the study)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hypofractionation control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive 40 Gy in 15 fractions to the entire breast or chest wall over three weeks and have had breast conservation surgery (BCS) or oncoplastic breast surgery(OBS) will receive an additional boost to the tumour site if and will receive sequential dose 12GY\4 fractions or SIB 8GY 15 fractions. The supraclavicular fossa will be treated in patients with node-positive disease or those who had received neoadjuvant chemotherapy . The IMLN will be irradiated in N2and N3 at first presentation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>. Ultrahypofractionation experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will receive 26 Gy in 5 fractions to the entire breast and or chest wall for one week only. The volume of this arm will be the same as the volume of the control arm as regard axillary nodes, supraclavicular and IMLN. Patients who have had breast conservation or oncoplastic breast surgery(OBS) will be given a boost. If a boost is given, SIB of 6 Gy in 5 fractions will be used (or a sequential boost of 12GY\4 fractions).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionation Radiotherapy.</intervention_name>
    <description>Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.</description>
    <arm_group_label>Hypofractionation control arm</arm_group_label>
    <other_name>3 weeks radiotherapy.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ultra-hypofractionation radiotherapy</intervention_name>
    <description>Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.</description>
    <arm_group_label>. Ultrahypofractionation experimental arm</arm_group_label>
    <other_name>1 week accelerated hypo-fractionation radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients 45 years of age or older who have had Oncoplastic Breast Surgery (OBS)&#xD;
             or total mastectomy with adequate axillary clearance and a negative margin.&#xD;
&#xD;
          -  Breast carcinomas that is invasive (TXN1-3M0, T0N2-3 M0, T1N2-3M0, T2N2-3M0, T3N0-3M0,&#xD;
             T4N0-3M0) whatever type of tumors biology.&#xD;
&#xD;
          -  All patients with locally advanced breast cancer who received neoadjuvant chemotherapy&#xD;
             and underwent either oncoplastic breast surgery or modified radical mastectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer at the time of diagnosis proved clinically or radiologically.&#xD;
&#xD;
          -  Postoperative positive margin.&#xD;
&#xD;
          -  Carcinomas in situ.&#xD;
&#xD;
          -  Mesenchymal breast lesions.&#xD;
&#xD;
          -  Locoregional recurrent breast cancer.&#xD;
&#xD;
          -  Synchronous bilateral breast cancer.&#xD;
&#xD;
          -  very early breast cancer (T1-2N0M0,T1N1M0).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female adult patients with breast</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nahla M Elmahdy, assistant lecturer</last_name>
    <phone>01026886840</phone>
    <email>nahla.youssif@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed S gaber, professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Osama R ElSherif, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.</citation>
    <PMID>33538338</PMID>
  </reference>
  <reference>
    <citation>Gany F, Ayash C, Raad N, Wu M, Roberts-Eversley N, Mahmoud H, Fouad Y, Fahmy Y, Asar H, Salama A, El-Shinawi M. Financial and food security challenges of Egyptian women undergoing breast cancer treatment. Support Care Cancer. 2020 Dec;28(12):5787-5794. doi: 10.1007/s00520-020-05426-9. Epub 2020 Mar 27.</citation>
    <PMID>32221669</PMID>
  </reference>
  <reference>
    <citation>Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019 Apr 10;11:151-164. doi: 10.2147/BCTT.S176070. eCollection 2019. Review.</citation>
    <PMID>31040712</PMID>
  </reference>
  <reference>
    <citation>Stapleton SM, Oseni TO, Bababekov YJ, Hung YC, Chang DC. Race/Ethnicity and Age Distribution of Breast Cancer Diagnosis in the United States. JAMA Surg. 2018 Jun 1;153(6):594-595. doi: 10.1001/jamasurg.2018.0035.</citation>
    <PMID>29516087</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Nahla Mohamed Elmahdy</investigator_full_name>
    <investigator_title>Assistant lecturer of clinical oncology sohag university hospitals</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

